Apogee Therapeutics, Inc. (APGE) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 9 Buy, 1 Hold.
The consensus price target is $105.63 (low: $83.00, high: $137.00), representing an upside of 19.4% from the current price $88.47.
Analysts estimate Earnings Per Share (EPS) of $-3.24 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2025: actual $-4.22 vs est $-4.20 (missed -0.5%). Analyst accuracy: 99%.
APGE Stock — 12-Month Price Forecast
$105.63
▲ +19.40% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Apogee Therapeutics, Inc., the average price target is $105.63, with a high forecast of $137.00, and a low forecast of $83.00.
The average price target represents a +19.40% change from the last price of $88.47.
Highest Price Target
$137.00
Average Price Target
$105.63
Lowest Price Target
$83.00
APGE Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Apogee Therapeutics, Inc. in the past 3 months
EPS Estimates — APGE
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.00
vs Est –$3.24
▲ 0.0% off
2025
Actual –$4.22
vs Est –$4.20
▼ 0.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — APGE
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
